TAIPEI, Taiwan–(BUSINESS WIRE)–PharmaEssentia’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the United States, and China, widening treatment options for patients with the chronic disease. In Europe, however, the ET indication remains unapproved, underscoring the gap between clinical advances and patient access across global markets. Developed and manufactured by the Taiwan-based biopharmaceutical company P